Asker Healthcare Group AB/Skr ASKER
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Asker Healthcare Group AB
Asker Healthcare Group AB operates in the healthcare industry, focusing on providing medical supplies, services, and equipment primarily to healthcare institutions. The company is involved in the distribution and logistics of medical consumables and advanced medical technology products. Headquartered in Sweden, Asker Healthcare Group serves markets across Europe, leveraging its extensive network to cater to hospitals, care homes, and other healthcare service providers. The company emphasizes efficient supply chain management and aims to support healthcare professionals with reliable product accessibility and quality service, ensuring continuity in patient care.
- Ticker
- Skr ASKER
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 4,885
- Headquarters
- Danderyd, Sweden
- Website
- www.asker.com
ASKER Metrics
BasicAdvanced
kr 27B
38.12
kr 1.87
-
kr 0.39
0.55%
Price and volume
Market cap
kr 27B
52-week high
kr 95.56
52-week low
kr 56.20
Average daily volume
552K
Dividend rate
kr 0.39
Financial strength
Current ratio
1.305
Quick ratio
0.773
Long term debt to equity
0.71
Total debt to equity
0.923
Dividend payout ratio (TTM)
21.78%
Interest coverage (TTM)
8.77%
Profitability
EBITDA (TTM)
1,880
Gross margin (TTM)
41.32%
Net profit margin (TTM)
3.80%
Operating margin (TTM)
7.01%
Effective tax rate (TTM)
21.23%
Revenue per employee (TTM)
kr 3,690,000
Management effectiveness
Return on assets (TTM)
4.78%
Return on equity (TTM)
10.49%
Valuation
Price to earnings (TTM)
38.124
Price to revenue (TTM)
1.513
Price to book
3.91
Price to tangible book (TTM)
-8.93
Price to free cash flow (TTM)
27.396
Free cash flow yield (TTM)
3.65%
Free cash flow per share (TTM)
2.597
Dividend yield (TTM)
0.55%
Forward dividend yield
0.55%
Growth
Revenue change (TTM)
13.40%
Earnings per share change (TTM)
46.07%
What the Analysts think about ASKER
Analyst ratings (Buy, Hold, Sell) for Asker Healthcare Group AB stock.
Analyst projections of the future price of Asker Healthcare Group AB stock.
Bulls say / Bears say
Second-quarter sales rose 18% and adjusted EBITA grew 24%; the adjusted margin improved to 10.0% from 9.5%. Adjusted operating cash flow also increased to SEK 330 million from SEK 211 million, pointing to stronger earnings and cash generation. (MFN.se)
Organic sales growth was 5% and organic adjusted EBITA growth was 6% in Q2, with management saying EBITA growth was ahead of a market growing at 3–4%. That suggests momentum is not solely dependent on acquisitions. (Stock Analysis)
Recent deals in Poland, Norway and the Baltics broaden Asker’s European reach and specialist product offering. A continuing flow of acquisitions could add new channels for growth if the group integrates them well. (Asker Healthcare Group AB)
Acquisitions supplied about 13 percentage points of Q2’s 18% sales growth, versus five points from organic growth. If deal activity slows or acquired businesses do not keep contributing, headline growth could cool materially. (BioStock)
Net debt rose to SEK 4.5 billion and leverage reached 2.37 times adjusted EBITDA, close to the group’s 2.5-times ceiling. Large earn-out payments added to cash outflows, leaving less room for further debt-funded deals or weaker trading. (BioStock)
A Simply Wall St analysis put the shares above its estimated DCF fair value of SEK 66.59. If earnings growth disappoints, a valuation that already assumes strong performance could leave the shares exposed to a re-rating. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
ASKER Financial Performance
Revenues and expenses
ASKER Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ASKER
AllUSDEURGBP
Fund name | Fund size | Skr ASKER weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.09% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.09% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.01% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.01% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.